Top Biotech Gainers: CDNA Soars On Medicare Policy, ATAI Acquired, ABT Lifts Outlook, APLM On Watch

CareDx shares jumped 35% after Medicare finalized its LCD for molecular testing, confirming coverage for its transplant surveillance portfolio effective Aug. 30, 2026.

Likely continued upside bias into the Aug. 30, 2026 effective date, with volatility around the July 30, 2026 Q2 results.

The article cites a finalized Medicare LCD and a specific effective date, which is a concrete demand catalyst; however, magnitude of incremental revenue is not quantified here.

AtaiBeckley surged 33% after agreeing to be acquired by Eli Lilly in a deal valued up to $3.8B with $2.8B upfront cash and up to $1.0B in CVRs.

Supportive for the stock while deal terms are digested; expect spread/volatility risk as closing approaches in Q3.

The article provides deal value, consideration structure, and expected closing quarter, which are directly tradable catalysts.

Abbott gained 10% after reporting Q2 results and raising its full-year adjusted EPS outlook to $5.45 to $5.60 from $5.38 to $5.58.

Near-term momentum likely, with follow-through dependent on whether investors view the outlook as sustainable across segments.

The article includes specific Q2 numbers and a revised EPS range, which are primary drivers of the same-day move.

Apollomics added 22% after the company regained Nasdaq MVLS compliance, with weekly gains exceeding 60% so far this week.

Potential for continued relief-rally, but upside may fade if no new clinical or financing catalyst follows.

The compliance closure is a concrete risk-removal event, but the article does not add new clinical efficacy or funding details beyond the compliance update.

Virax Biolabs rose 13% after CEO James Foster issued a shareholder update citing a $3.3M capital raise, restored Nasdaq compliance after a 1-for-25 reverse split, and a multi-country supply agreement.

Moderately bullish bias, with sensitivity to execution of platform milestones and further financing needs.

The update includes multiple concrete items (capital raise, compliance, supply agreement), but the article lacks quantified revenue impact.

Entera Bio jumped 12% as investors reacted to its plan to initiate a Phase 3 trial for EB613 in late 2026, with topline results expected in H2 2028.

Likely supportive into late-2026 trial initiation, with interim volatility around trial design and financing.

The article provides a specific Phase 3 start window and topline timing, but no new efficacy/safety data are disclosed.